rilonacept regeneron (previously arcalyst)
regeneron uk limited - rilonacept - la cryopyrine syndromes périodiques associés À la - immunosuppresseurs - rilonacept regeneron est indiqué pour le traitement des syndromes périodiques associés à la cryopyrine (caps) présentant des symptômes sévères, y compris le syndrome de froid auto-inflammatoires familial (fcas) et le syndrome de muckle-wells (mws), chez les adultes et les enfants de 12 ans et plus âgés.
metfogamma 1000 mg, comprimé pelliculé sécable
generosana srl - metformine base - comprimé - 780 mg - composition pour un comprimé > metformine base : 780 mg . sous forme de : chlorhydrate de metformine 1000 mg - antidiabetiques oraux
metfogamma 500 mg, comprimé pelliculé
generosana srl - metformine base - comprimé - 390 mg - composition pour un comprimé > metformine base : 390 mg . sous forme de : chlorhydrate de metformine 500 mg - antidiabetiques oraux
metfogamma 850 mg, comprimé pelliculé
generosana srl - metformine base - comprimé - 662,8 mg - composition pour un comprimé > metformine base : 662,8 mg . sous forme de : chlorhydrate de metformine 850 mg - antidiabetiques oraux
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - carcinome, cellule squameuse - agents antinéoplasiques - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
synovex choice implant
zoetis canada inc - acétate de trenbolone; benzoate d'estradiol - implant - 100mg; 14mg - acétate de trenbolone 100mg; benzoate d'estradiol 14mg - bétails; bétails
synovex s implant
zoetis canada inc - progestérone; benzoate d'estradiol - implant - 200mg; 20mg - progestérone 200mg; benzoate d'estradiol 20mg - objet - bétails
synovex h implant
zoetis canada inc - propionate de testostérone; benzoate d'estradiol - implant - 200mg; 20mg - propionate de testostérone 200mg; benzoate d'estradiol 20mg - objet - bétails
synovex c implant
zoetis canada inc - progestérone; benzoate d'estradiol - implant - 100mg; 10mg - progestérone 100mg; benzoate d'estradiol 10mg - objet - bétails
synovex plus implant
zoetis canada inc - acétate de trenbolone; benzoate d'estradiol - implant - 200mg; 28mg - acétate de trenbolone 200mg; benzoate d'estradiol 28mg - bétails; bétails